Literature DB >> 23412431

Effect of increased viral replication and infectivity enhancement on radioiodide uptake and oncolytic activity of adenovirus vectors expressing the sodium iodide symporter.

M J Oneal1, M A Trujillo, J Davydova, S McDonough, M Yamamoto, J C Morris.   

Abstract

Our laboratory has investigated replicating adenovirus-human sodium iodide symporter (Ad-hNIS) vectors in a combinatorial oncolytic approach known as radiovirotherapy. However, hNIS-mediated iodide sequestration requires an intact cell membrane, and the enhancement of infectivity may alter the radioiodide accumulation in vivo. To assess these effects, we constructed Ad-NIS vectors expressing NIS from the major late promoter. Viral tropism was altered using a hybrid Ad5/3 fiber, and rates of viral spread altered through expression of the Ad death protein (ADP). The hybrid 5/3 fiber enhanced Ad-mediated cytolysis and radioisotope uptake in vitro. Replicating ADP-lacking viral vectors showed levels of uptake similar to non-replicating vectors that declined as cells lysed. ADP expression enhanced the rate of cell lysis and viral release, but reduced the peak and duration of radioiodide uptake. SPECT-computed tomography imaging showed the Ad5/3-noADP-hNIS vector induced significantly more isotope uptake than other vector structures, indicating that viral spread may not always make up for the reduced NIS expression as in our work with prostate cancer. These results indicate that replicating, infectivity-enhanced Ad-NIS vectors provide superior overall efficacy, but also indicate that the effect of replication speed requires tumor and model-specific testing.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23412431     DOI: 10.1038/cgt.2013.4

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  5 in total

1.  Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene.

Authors:  Sarah Urnauer; Stephan Morys; Ana Krhac Levacic; Andrea M Müller; Christina Schug; Kathrin A Schmohl; Nathalie Schwenk; Christian Zach; Janette Carlsen; Peter Bartenstein; Ernst Wagner; Christine Spitzweg
Journal:  Mol Ther       Date:  2016-05-09       Impact factor: 11.454

2.  Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses.

Authors:  Lisa Koodie; Matthew G Robertson; Malavika Chandrashekar; George Ruth; Michele Dunning; Richard W Bianco; Julia Davydova
Journal:  Cancers (Basel)       Date:  2019-02-08       Impact factor: 6.639

3.  Cancer imaging and therapy utilizing a novel NIS-expressing adenovirus: The role of adenovirus death protein deletion.

Authors:  Matthew Glen Robertson; Benjamin Bruce Eidenschink; Eriko Iguchi; Stanislav O Zakharkin; Christopher J LaRocca; Ezequiel J Tolosa; Mark J Truty; Kari Jacobsen; Martin E Fernandez-Zapico; Julia Davydova
Journal:  Mol Ther Oncolytics       Date:  2021-03-05       Impact factor: 7.200

Review 4.  The use of the NIS reporter gene for optimizing oncolytic virotherapy.

Authors:  Amber Miller; Stephen J Russell
Journal:  Expert Opin Biol Ther       Date:  2015-10-12       Impact factor: 4.388

Review 5.  Targeting strategies of adenovirus‑mediated gene therapy and virotherapy for prostate cancer (Review).

Authors:  Zhonglin Cai; Haidi Lv; Wenjuan Cao; Chuan Zhou; Qiangzhao Liu; Hui Li; Fenghai Zhou
Journal:  Mol Med Rep       Date:  2017-09-13       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.